Drug Trial Radar · NCT04106778
DMT310-003 Topical in the Treatment of Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Jul 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
181
Actual
Start
Oct 10, 2019
Primary completion
May 4, 2020
Study completion May 4, 2020
Sponsor
- Lead sponsor
- Dermata TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
DMT310Drug
Topical Powder
PlaceboDrug
Placebo Topical Powder
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy as measured by lesion countsTime frame: 12 Weeks
- Efficacy as measured by Investigator Global Assessment (IGA)Time frame: 12 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermata Investigational Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.